Clinical Trials

73 enrolled

Colorectal Neoplasms, Dihydropyrimidine Dehydrogenase Deficiency

NCT06265285 2025-12-04

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

50 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT04117087 2025-12-03

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Phase 1 Active not recruiting

27 enrolled

Phase 1/2 Active not recruiting

Colonic Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04017650 2025-11-20

Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer

38 enrolled

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Disease Progression

NCT04912765 2025-09-23

Neoantigen Dendritic Cell Vaccine and Nivolumab in HCC and Liver Metastases From CRC

60 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms, Colorectal Neoplasms

NCT03547999 2025-07-22

A Trial of Perioperative CV301 Vaccination in Combination With Nivolumab and Systemic Chemotherapy for Metastatic CRC

Phase 2 Terminated

17 enrolled 16 charts

Fowlpox, Colorectal Neoplasms

NCT05310643 2025-07-01

NIPIRESCUE

30 enrolled

Colorectal Neoplasms

NCT03642067 2025-06-15

Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer

59 enrolled 11 charts

Colonic Neoplasms, Rectal Neoplasms, Spinocerebellar Degenerations, Colorectal Neoplasms

NCT03879811 2025-05-15

Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer

Phase 2 Withdrawn

Colorectal Neoplasms

NCT04072198 2025-03-13

NIVACOR

73 enrolled

Colorectal Neoplasms

NCT05061017 2025-03-07

Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

DermatologicGastrointestinal

13 enrolled 25 charts

Melanoma, Colorectal Neoplasms

NCT03190174 2025-02-17

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers

Phase 1/2 Completed

34 enrolled 14 charts

DermatologicGastrointestinalGenitourinarySarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Chordoma, Carcinoma, Hepatocellular, Melanoma, Sarcoma, Sarcoma, Ewing, Colorectal Neoplasms, Desmoid Tumors, Perivascular Epithelioid Cell Neoplasms

NCT03800602 2024-09-05

Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer

29 enrolled 7 charts

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT03981146 2024-08-13

ANICCA

35 enrolled

Phase 2 Active not recruiting

Colorectal Neoplasms

NCT03867799 2024-06-14

iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer

25 enrolled

Colorectal Neoplasms

NCT03373188 2024-03-20

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Phase 1 Completed

10 enrolled

Pancreatic Neoplasms, Colorectal Neoplasms

NCT03791398 2023-02-17

379

Phase 1/2 Terminated

13 enrolled 11 charts

Colonic Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT03832621 2022-04-04

MAYA

135 enrolled

Colorectal Neoplasms

NCT04430985 2021-10-27

IMMUNOX

Phase 2 Withdrawn

Colorectal Neoplasms

NCT03576963 2021-04-05

Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer

Phase 1/2 Withdrawn